Genome News and Research

RSS

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

18 Jun 2010

AMP raises ethical, laboratory practice concerns in whole genome sequencing at SACHGS meeting

Today, the Association for Molecular Pathology (AMP) presented public comments to the Secretary's Advisory Committee on Genetics, Health and Society (SACHGS) meeting focused on whole genome sequencing. In anticipation of advances in sequencing and its incorporation into clinical practice, AMP raised ethical and laboratory practice concerns for the Committee's consideration.

17 Jun 2010

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA® (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The results will be presented today in Rome at the 2010 Congress of the European League Against Rheumatism (EULAR).

17 Jun 2010

Researchers sequence genome of Amerindian strain of the gastric bug H. pylori

An international team of researchers led by scientists at the Virginia Bioinformatics Institute at Virginia Tech have sequenced the genome of an Amerindian strain of the gastric bug Helicobacter pylori, confirming the out-of-Africa migration of this bacterial stowaway to the New World. Experiments in animals have highlighted how specific genes in the bacterial strain may be crucial to the onset of inflammation and disease.

17 Jun 2010

Stony Brook team creates live attenuated influenza virus vaccine by computer-aided rational design

A team of molecular biologists and computer scientists at Stony Brook University have used a novel method to weaken (attenuate) influenza virus by way of designing hundreds of mutations to its genetic code to create an effective vaccine. Reported online and in the July issue of Nature Biotechnology, the method may be a major step in developing more effective and safe vaccines against influenza, which claims 250,000 to 500,000 lives annually worldwide, partly because existing vaccines are not fully effective.

17 Jun 2010

Report on treatment trends in systemic lupus erythematosus

BioTrends is pleased to announce the upcoming publication of a new syndicated report, TreatmentTrends®: Systemic Lupus Erythematosus (SLE). This report will provide a comprehensive market overview of current and future treatment trends in SLE based on a primary research study fielded with 102 rheumatologists in the U.S. during the first week in June.

16 Jun 2010

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

The Institute for Systems Biology (ISB) of Seattle, WA, is collaborating with the Gladstone Institute of Neurological Disease (GIND) and its Taube-Koret Center for Huntington's Disease Research to use whole-genome sequencing to identify genes and novel drug targets related to the onset and progression of Huntington's disease (HD). The research team, led by GIND associate director and senior investigator Steven Finkbeiner, MD, PhD, will also use induced pluripotent stem (iPS) cells from patients with HD to screen for drugs that might delay, prevent, or even reverse this devastating condition.

16 Jun 2010

ExonHit Therapeutics, Genmab A/S sign agreement for selection of novel splice variants

ExonHit Therapeutics today announced the signing of an exclusive agreement with Genmab A/S for a selection of novel splice variants, identified as part of a successful pilot study, that have the potential to be therapeutic targets for breast cancer. Genmab retains exclusive development and commercialization rights on 10 events out of a breast cancer database developed using ExonHit's genome-wide SpliceArray technology (RNA splicing analysis platform covering the entire genome).

15 Jun 2010

Human Genome Sciences receives FDA feedback for ZALBIN BLA

Human Genome Sciences, Inc. today announced that it has received preliminary written feedback from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) seeking approval in the United States to market 900-mcg ZALBIN™ (albinterferon alfa-2b, known in Europe as JOULFERON®) dosed every two weeks for the treatment of chronic hepatitis C. FDA has expressed concerns regarding the risk benefit assessment of ZALBIN dosed at 900-mcg every two weeks.

14 Jun 2010

Winners of BioMed Central Annual Research Awards announced

The winners of BioMed Central's 4th Annual Research Awards were announced at London's Swiss Re Tower last night. The event was attended by shortlisted authors, eminent researchers, publishers, open access advocates and science journalists from around the world.

14 Jun 2010

CNVs increases patients' susceptibility to severe sepsis

Genetic makeup has been identified as a key factor leading to the development of sepsis, a systemic inflammatory reaction that occurs during infection. Sepsis is considered severe when associated with organ dysfunction.

14 Jun 2010

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

Research on genetic mutations could lead to accurate diagnosis of USH, says scientist

Usher syndrome, an inherited condition involving both hearing and vision loss, is not a simply recessively inherited disease, a scientist will tell the annual conference of the European Society of Human Genetics today (Saturday). Dr. Hanno Bolz, Associate Medical Director of the Bioscientia Centre for Human Genetics, Ingelheim, Germany, and active in teaching and research at the University Hospital of Cologne, will say that his team's research challenges the traditional view that USH was inherited as a single gene disorder, and shows that it may result from at least two different genetic mutations.

14 Jun 2010

Interactions between human and microbial cells determine health, physical well-being: Researchers

At birth, your body was 100-percent human in terms of cells. At death, about 10-percent of the cells in your body will be human and the remaining 90-percent will be microorganisms. That makes you a "supraorganism," and it is the interactions between your human and microbial cells that go a long way towards determining your health and physical well-being, especially your resistance to infectious diseases.

11 Jun 2010

Researchers to present advanced treatment strategies for eye diseases at NEI symposium

The National Eye Institute (NEI), part of the National Institutes of Health (NIH), is bringing together premier researchers who translate molecular and genetic approaches from the laboratory to visual system diseases in the clinic.

11 Jun 2010

Interpretation of multiple gene function may hold clue to autism

Deciphering the functions of multiple rare genes may be at the core of understanding the genetic factors that cause autism spectrum disorders (ASDs), according to a new study published June 9 in the journal Nature by dozens of top autism researchers around the world, including Yale Child Study Center Director Fred R. Volkmar, M.D.

11 Jun 2010

Study demonstrates p53 protein becomes activated during gamete formation

Protein p53 is known as the guardian of the genome since it is basic for the genome's integrity by preventing the accumulation of mutations originating either by the cell's own mechanisms or by the action of external agents.

11 Jun 2010

New methodology may help control influenza

Scientists have uncovered the flu's secret formula for effectively evolving within and between host species: balance. The key lies with the flu's unique replication process, which has evolved to produce enough mutations for the virus to spread and adapt to its host environment, but not so many that unwanted genomic mutations lead to the flu's demise (catastrophic mutagenesis).

11 Jun 2010

NanoString Technologies launches new solution to detect CNVs in human genomic samples

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the launch of its early access program for a unique new solution that detects copy number variation in human genomic samples. The program was announced in conjunction with the company's participation in the European Human Genetics Conference in Gothenburg, Sweden.

From NanoString Technologies 10 Jun 2010

Researchers validate effectiveness of genome sequencing process for hereditary genetic diseases

A research team led by Dr. Nada Jabado at the MUHC Research Institute and Dr. Jacek Majewski at McGill University has proven for the first time that it is possible to identify any genetic disease in record time thanks to a powerful and reliable exome sequencing method. The exome, a small part of the genome ((less than) 2%), is of crucial interest with regard to research on genetic diseases as it accounts for 85% of mutations.

10 Jun 2010

Genome News and Research

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

AMP raises ethical, laboratory practice concerns in whole genome sequencing at SACHGS meeting

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Researchers sequence genome of Amerindian strain of the gastric bug H. pylori

Stony Brook team creates live attenuated influenza virus vaccine by computer-aided rational design

Report on treatment trends in systemic lupus erythematosus

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

ExonHit Therapeutics, Genmab A/S sign agreement for selection of novel splice variants

Human Genome Sciences receives FDA feedback for ZALBIN BLA

Winners of BioMed Central Annual Research Awards announced

CNVs increases patients' susceptibility to severe sepsis

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

Research on genetic mutations could lead to accurate diagnosis of USH, says scientist

Interactions between human and microbial cells determine health, physical well-being: Researchers

Researchers to present advanced treatment strategies for eye diseases at NEI symposium

Interpretation of multiple gene function may hold clue to autism

Study demonstrates p53 protein becomes activated during gamete formation

New methodology may help control influenza

NanoString Technologies launches new solution to detect CNVs in human genomic samples

Researchers validate effectiveness of genome sequencing process for hereditary genetic diseases

Genetics & Genomics - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News